SARS-COV和MERS-COV以及SARS-COV-2的研究进展  

Research progress on SARS,MERS and COVID-19 coronavirus

作　　者：董家潇 李修政 张忠伟 严佳栋 DONG Jia-xiao;LI Xiu-zheng;ZHANG Zhong-wei;YAN Jia-dong(Department of Pharmacology,the First People′s Hospital of Zhang-Jia-Gang City,Suzhou,Jiangsu215000,China)

机构地区：[1]苏州大学附属张家港医院药学部,江苏苏州215000

出　　处：《中国病毒病杂志》2021年第5期381-387,共7页Chinese Journal of Viral Diseases

摘　　要：β-冠状病毒(β-coronavirus,β-COV)是一类可导致人类呼吸道感染的相关病毒,在自然界中广泛存在,并可对人或动物造成严重危害。该病毒感染具有传染性高、流行性广、突发性强且无有效预防用药等特点,对世界各国及其公民造成较大的医疗负担。本文主要对严重急性呼吸综合征冠状病毒(severe acute respiratory syndrome coronavirus,SARS-COV)和中东呼吸综合征冠状病毒(Middle East respiratory syndrome coronavirus,MERS-COV),以及2019年12月以来的新型冠状病毒(severe acute respiratory syndrome coronavirus 2,SARS-COV-2)的流行概况、传播途径、致病性及致病机制、药物与疫苗等最新进展进行综述,旨在为更好地防控高致病性人冠状病毒提供依据。β-Coronavirus(β-CoV)contains a type of related viruses that can cause human respiratory infections.It is widespread in nature and can cause serious harm to humans or animals.The infection of the virus has the characteristics of high infectivity,wide epidemic,strong suddenness,and without effective preventive medication,which imposes a large medical burden on the country and patients.This review briefly summarizes the epidemic situation,transmission route,pathogenicity,pathogenesis and latest progress in drugs and vaccines of acute respiratory syndrome coronavirus(SARS-CoV),Middle East respiratory syndrome coronavirus(MERS-CoV)and the severe acute respiratory syndrome coronavirus 2(SARS-COV-2)since December 2019.

关 键 词：β-冠状病毒 SARS-COV MERS-COV SARS-COV-2 

分 类 号：R563.1[医药卫生—呼吸系统]